MedTrace Logo

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

NCT04612894 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2020-11-03

No results posted yet for this study

Summary

To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.

Conditions

Interventions

DRUG

Camrelizumab and Apatinib

All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment

PROCEDURE

surgery

Perform surgery if operable after neoadjuvant therapy

PROCEDURE

core needle biopsy

Perform core needle biopsy if inoperable after neoadjuvant therapy

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-12-01
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04612894 on ClinicalTrials.gov